The Medical University of South Carolina (MUSC) Division of Hematology & Oncology has a longstanding international reputation for excellence in research. Division faculty are involved in bench to bedside research, from basic laboratory experiments to conducting experimental clinical treatments, with the goal of providing better treatment options for patients with cancer and hematologic disorders. Their comprehensive treatment protocols include an ever expanding clinical trials portfolio offering studies for most types of cancer. As an NCI-Designated Cancer Center, Hollings Cancer Center (HCC) offers clinical trials and therapies not available elsewhere in South Carolina. Clinical and translational research at HCC and MUSC benefits from a centralized HCC Clinical Trials Office, an NIH-funded Clinical and Translational Science Award, and an NCI-funded Paul Calabresi K12 Program.
The Division’s benign hematologists conduct translational research regarding new diagnostic tests for the management of bleeding and thrombotic disorders along with basic research related to hemostasis, thrombosis, and wound healing. Clinical research on the use of new approaches to manage bleeding and thrombosis continue as part of national and international groups targeting life-threatening blood disorders.
Lab of Michael B. Lilly, M.D.
Lab of John M. Wrangle, M.D.